COVID-19 vaccination in advanced skin cancer patients receiving systemic anticancer treatment: A prospective singlecenter study investigating seroconversion rates
BackgroundCOVID-19 vaccination reduces risk of SARS-CoV-2 infection, COVID-19 severity and death. However, the rate of seroconversion after COVID-19 vaccination in cancer patients requiring systemic anticancer treatment is poorly investigated. The aim of the present study was to determine the rate o...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-08-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.879876/full |
| _version_ | 1818000502790553600 |
|---|---|
| author | Georg C. Lodde Melanie Fiedler Ulf Dittmer Jan-Malte Placke Philipp Jansen Jürgen C. Becker Jürgen C. Becker Jürgen C. Becker Lisa Zimmer Elisabeth Livingstone Dirk Schadendorf Dirk Schadendorf Wiebke Sondermann Selma Ugurel Selma Ugurel |
| author_facet | Georg C. Lodde Melanie Fiedler Ulf Dittmer Jan-Malte Placke Philipp Jansen Jürgen C. Becker Jürgen C. Becker Jürgen C. Becker Lisa Zimmer Elisabeth Livingstone Dirk Schadendorf Dirk Schadendorf Wiebke Sondermann Selma Ugurel Selma Ugurel |
| author_sort | Georg C. Lodde |
| collection | DOAJ |
| description | BackgroundCOVID-19 vaccination reduces risk of SARS-CoV-2 infection, COVID-19 severity and death. However, the rate of seroconversion after COVID-19 vaccination in cancer patients requiring systemic anticancer treatment is poorly investigated. The aim of the present study was to determine the rate of seroconversion after COVID-19 vaccination in advanced skin cancer patients under active systemic anticancer treatment.MethodsThis prospective single-center study of a consecutive sample of advanced skin cancer patients was performed from May 2020 until October 2021. Inclusion criteria were systemic treatment for advanced skin cancer, known COVID-19 vaccination status, repetitive anti-SARS-CoV-2-S IgG serum quantification and first and second COVID-19 vaccination. Primary outcome was the rate of anti-SARS-CoV-2-S IgG seroconversion after complete COVID-19 vaccination.ResultsOf 60 patients with advanced skin cancers, 52 patients (86.7%) received immune checkpoint inhibition (ICI), seven (11.7%) targeted agents (TT), one (1.7%) chemotherapy. Median follow-up time was 12.7 months. During study progress ten patients had died from skin cancer prior to vaccination completion, six patients were lost to follow-up and three patients had refused vaccination. 41 patients completed COVID-19 vaccination with two doses and known serological status. Of those, serum testing revealed n=3 patients (7.3%) as anti-SARS-CoV-2-S IgG positive prior to vaccination, n=32 patients (78.0%) showed a seroconversion, n=6 patients (14.6%) did not achieve a seroconversion. Patients failing serological response were immunocompromised due to concomitant hematological malignancy, previous chemotherapy or autoimmune disease requiring immunosuppressive comedications. Immunosuppressive comedication due to severe adverse events of ICI therapy did not impair seroconversion following COVID-19 vaccination. Of 41 completely vaccinated patients, 35 (85.4%) were under treatment with ICI, five (12.2%) with TT, and one (2.4%) with chemotherapy. 27 patients (65.9%) were treated non adjuvantly. Of these patients, 13 patients had achieved objective response (complete/partial response) as best tumor response (48.2%).Conclusion and relevanceRate of anti-SARS-CoV-2-S IgG seroconversion in advanced skin cancer patients under systemic anticancer treatment after complete COVID-19 vaccination is comparable to other cancer entities. An impaired serological response was observed in patients who were immunocompromised due to concomitant diseases or previous chemotherapies. Immunosuppressive comedication due to severe adverse events of ICI did not impair the serological response to COVID-19 vaccination. |
| first_indexed | 2024-04-14T03:22:32Z |
| format | Article |
| id | doaj.art-3925aa3664cc4ef0a1cbb5fd4747520f |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-14T03:22:32Z |
| publishDate | 2022-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-3925aa3664cc4ef0a1cbb5fd4747520f2022-12-22T02:15:16ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-08-011210.3389/fonc.2022.879876879876COVID-19 vaccination in advanced skin cancer patients receiving systemic anticancer treatment: A prospective singlecenter study investigating seroconversion ratesGeorg C. Lodde0Melanie Fiedler1Ulf Dittmer2Jan-Malte Placke3Philipp Jansen4Jürgen C. Becker5Jürgen C. Becker6Jürgen C. Becker7Lisa Zimmer8Elisabeth Livingstone9Dirk Schadendorf10Dirk Schadendorf11Wiebke Sondermann12Selma Ugurel13Selma Ugurel14Department of Dermatology, University Hospital Essen, Essen, GermanyInstitute for Virology, University Hospital Essen, Essen, GermanyInstitute for Virology, University Hospital Essen, Essen, GermanyDepartment of Dermatology, University Hospital Essen, Essen, GermanyDepartment of Dermatology, University Hospital Essen, Essen, GermanyDepartment of Dermatology, University Hospital Essen, Essen, GermanyTranslational Skin Cancer Research (TSCR), University of Duisburg/Essen, Essen, GermanyGerman Consortium for Translational Cancer Research (DKTK), Partner Site Essen/Düsseldorf, Essen/Düsseldorf, GermanyDepartment of Dermatology, University Hospital Essen, Essen, GermanyDepartment of Dermatology, University Hospital Essen, Essen, GermanyDepartment of Dermatology, University Hospital Essen, Essen, GermanyGerman Consortium for Translational Cancer Research (DKTK), Partner Site Essen/Düsseldorf, Essen/Düsseldorf, GermanyDepartment of Dermatology, University Hospital Essen, Essen, GermanyDepartment of Dermatology, University Hospital Essen, Essen, GermanyGerman Consortium for Translational Cancer Research (DKTK), Partner Site Essen/Düsseldorf, Essen/Düsseldorf, GermanyBackgroundCOVID-19 vaccination reduces risk of SARS-CoV-2 infection, COVID-19 severity and death. However, the rate of seroconversion after COVID-19 vaccination in cancer patients requiring systemic anticancer treatment is poorly investigated. The aim of the present study was to determine the rate of seroconversion after COVID-19 vaccination in advanced skin cancer patients under active systemic anticancer treatment.MethodsThis prospective single-center study of a consecutive sample of advanced skin cancer patients was performed from May 2020 until October 2021. Inclusion criteria were systemic treatment for advanced skin cancer, known COVID-19 vaccination status, repetitive anti-SARS-CoV-2-S IgG serum quantification and first and second COVID-19 vaccination. Primary outcome was the rate of anti-SARS-CoV-2-S IgG seroconversion after complete COVID-19 vaccination.ResultsOf 60 patients with advanced skin cancers, 52 patients (86.7%) received immune checkpoint inhibition (ICI), seven (11.7%) targeted agents (TT), one (1.7%) chemotherapy. Median follow-up time was 12.7 months. During study progress ten patients had died from skin cancer prior to vaccination completion, six patients were lost to follow-up and three patients had refused vaccination. 41 patients completed COVID-19 vaccination with two doses and known serological status. Of those, serum testing revealed n=3 patients (7.3%) as anti-SARS-CoV-2-S IgG positive prior to vaccination, n=32 patients (78.0%) showed a seroconversion, n=6 patients (14.6%) did not achieve a seroconversion. Patients failing serological response were immunocompromised due to concomitant hematological malignancy, previous chemotherapy or autoimmune disease requiring immunosuppressive comedications. Immunosuppressive comedication due to severe adverse events of ICI therapy did not impair seroconversion following COVID-19 vaccination. Of 41 completely vaccinated patients, 35 (85.4%) were under treatment with ICI, five (12.2%) with TT, and one (2.4%) with chemotherapy. 27 patients (65.9%) were treated non adjuvantly. Of these patients, 13 patients had achieved objective response (complete/partial response) as best tumor response (48.2%).Conclusion and relevanceRate of anti-SARS-CoV-2-S IgG seroconversion in advanced skin cancer patients under systemic anticancer treatment after complete COVID-19 vaccination is comparable to other cancer entities. An impaired serological response was observed in patients who were immunocompromised due to concomitant diseases or previous chemotherapies. Immunosuppressive comedication due to severe adverse events of ICI did not impair the serological response to COVID-19 vaccination.https://www.frontiersin.org/articles/10.3389/fonc.2022.879876/fullCOVID-19 vaccinationseroconversionskin cancerimmune checkpoint inhibitiontargeted therapy |
| spellingShingle | Georg C. Lodde Melanie Fiedler Ulf Dittmer Jan-Malte Placke Philipp Jansen Jürgen C. Becker Jürgen C. Becker Jürgen C. Becker Lisa Zimmer Elisabeth Livingstone Dirk Schadendorf Dirk Schadendorf Wiebke Sondermann Selma Ugurel Selma Ugurel COVID-19 vaccination in advanced skin cancer patients receiving systemic anticancer treatment: A prospective singlecenter study investigating seroconversion rates Frontiers in Oncology COVID-19 vaccination seroconversion skin cancer immune checkpoint inhibition targeted therapy |
| title | COVID-19 vaccination in advanced skin cancer patients receiving systemic anticancer treatment: A prospective singlecenter study investigating seroconversion rates |
| title_full | COVID-19 vaccination in advanced skin cancer patients receiving systemic anticancer treatment: A prospective singlecenter study investigating seroconversion rates |
| title_fullStr | COVID-19 vaccination in advanced skin cancer patients receiving systemic anticancer treatment: A prospective singlecenter study investigating seroconversion rates |
| title_full_unstemmed | COVID-19 vaccination in advanced skin cancer patients receiving systemic anticancer treatment: A prospective singlecenter study investigating seroconversion rates |
| title_short | COVID-19 vaccination in advanced skin cancer patients receiving systemic anticancer treatment: A prospective singlecenter study investigating seroconversion rates |
| title_sort | covid 19 vaccination in advanced skin cancer patients receiving systemic anticancer treatment a prospective singlecenter study investigating seroconversion rates |
| topic | COVID-19 vaccination seroconversion skin cancer immune checkpoint inhibition targeted therapy |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.879876/full |
| work_keys_str_mv | AT georgclodde covid19vaccinationinadvancedskincancerpatientsreceivingsystemicanticancertreatmentaprospectivesinglecenterstudyinvestigatingseroconversionrates AT melaniefiedler covid19vaccinationinadvancedskincancerpatientsreceivingsystemicanticancertreatmentaprospectivesinglecenterstudyinvestigatingseroconversionrates AT ulfdittmer covid19vaccinationinadvancedskincancerpatientsreceivingsystemicanticancertreatmentaprospectivesinglecenterstudyinvestigatingseroconversionrates AT janmalteplacke covid19vaccinationinadvancedskincancerpatientsreceivingsystemicanticancertreatmentaprospectivesinglecenterstudyinvestigatingseroconversionrates AT philippjansen covid19vaccinationinadvancedskincancerpatientsreceivingsystemicanticancertreatmentaprospectivesinglecenterstudyinvestigatingseroconversionrates AT jurgencbecker covid19vaccinationinadvancedskincancerpatientsreceivingsystemicanticancertreatmentaprospectivesinglecenterstudyinvestigatingseroconversionrates AT jurgencbecker covid19vaccinationinadvancedskincancerpatientsreceivingsystemicanticancertreatmentaprospectivesinglecenterstudyinvestigatingseroconversionrates AT jurgencbecker covid19vaccinationinadvancedskincancerpatientsreceivingsystemicanticancertreatmentaprospectivesinglecenterstudyinvestigatingseroconversionrates AT lisazimmer covid19vaccinationinadvancedskincancerpatientsreceivingsystemicanticancertreatmentaprospectivesinglecenterstudyinvestigatingseroconversionrates AT elisabethlivingstone covid19vaccinationinadvancedskincancerpatientsreceivingsystemicanticancertreatmentaprospectivesinglecenterstudyinvestigatingseroconversionrates AT dirkschadendorf covid19vaccinationinadvancedskincancerpatientsreceivingsystemicanticancertreatmentaprospectivesinglecenterstudyinvestigatingseroconversionrates AT dirkschadendorf covid19vaccinationinadvancedskincancerpatientsreceivingsystemicanticancertreatmentaprospectivesinglecenterstudyinvestigatingseroconversionrates AT wiebkesondermann covid19vaccinationinadvancedskincancerpatientsreceivingsystemicanticancertreatmentaprospectivesinglecenterstudyinvestigatingseroconversionrates AT selmaugurel covid19vaccinationinadvancedskincancerpatientsreceivingsystemicanticancertreatmentaprospectivesinglecenterstudyinvestigatingseroconversionrates AT selmaugurel covid19vaccinationinadvancedskincancerpatientsreceivingsystemicanticancertreatmentaprospectivesinglecenterstudyinvestigatingseroconversionrates |